NMDA
● DXM 1.59 · ■ DXO 0.22 · n in the article = 4
DXM FAQ 1997: selective audit by topic
What is known about NMDA, sigma-1 and sigma-2; how to read older PCP2 labels and the receptor ladder.
Xiao et al. table, audit §4. A common logarithmic axis; further left is a lower Ki in that assay.
The table compares Ki values from different biological systems. Ki describes binding; functional potency, clinical effect and brain target occupancy are distinct characteristics.
● DXM 1.59 · ■ DXO 0.22 · n in the article = 4
● DXM 1.67 · ■ DXO 2.85 · n in the article = 2
● DXM 14.70 · ■ DXO 9.98 · n in the article = 2
● DXM 0.0084 · ■ DXO 0.14 · n in the article = 2
● DXM 20.51 · ■ DXO 5.67 · n in the article = 2
n is the number of experiments reported in this article.
This is a preclinical study of deuterated DXM with bupropion. All authors disclosed employment at Salubris. The conflict of interest requires disclosure and independent confirmation of the conclusions, but does not in itself invalidate the table. 8
Audit reference №8 · Assay systems and conflict of interest · Plasma concentration and receptor occupancy
PCP2 is an older label for binding sites. Its association with DAT and its use to explain the first plateau remain hypotheses.
Remains a hypothesisAccording to the 2026 audit · edition
What was examined: Meoni studied dextromethorphan binding sites in rat brain and obtained evidence linking part of the observations to serotonin transport. Xiao’s modern paper examines several known targets.
Limits of the conclusion: Establishing a molecular target requires independent evidence on the identity of the site and the function of the protein.
Sources: Xiao — DXM and DXO target binding Meoni — DM2 binding sites
Historical paraphrase · FAQ 4.0 · 1997 · §9.2.2 White proposed a link between PCP2 and dopamine reuptake.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.2 · Contribution of the PCP2 Binding Site
DM2 findings are better described through the conditions of the particular experiment. Some older observations are consistent with sites associated with serotonin transport.
ClarifiedAccording to the 2026 audit · edition
What was examined: In Meoni’s rat-brain study, binding was sodium-dependent; distribution and mutual displacement with paroxetine supported an association with the serotonin uptake system.
Limits of the conclusion: The older labels grouped different experimental observations. Each site requires its own molecular identification.
Sources: Meoni — DM2 binding sites
Historical paraphrase · FAQ 4.0 · 1997 · §9.2.1 The FAQ links the second DXM binding site to PCP2 with near certainty.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.1 · General Information
The structure of sigma-1 was later published, and sigma-2 was identified as TMEM97. These discoveries update the older description.
ClarifiedAccording to the 2026 audit · edition
What was examined: Schmidt presented the crystal structure of human sigma-1. Alon showed that TMEM97 corresponds to sigma-2.
Limits of the conclusion: Molecular descriptions help investigate receptor functions. Receptor function and a particular subjective effect belong to different levels of description.
Sources: Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97
Historical paraphrase · FAQ 4.0 · 1997 · §10.2 The FAQ reflects early uncertainty about the cellular location and nature of sigma receptors.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2 · What are Sigma Receptors?
This explanation remains a hypothesis. Sigma-1 findings in experimental models and prescription labeling concern other endpoints.
Remains a hypothesisAccording to the 2026 audit · edition
What was examined: Nguyen examined antidepressant-like effects of DXM in a mouse model. The Auvelity label describes DXM’s pharmacological targets and notes uncertainty about the mechanism of therapeutic action.
Limits of the conclusion: A mouse behavioral model and human subjective experiences require different methods of evaluation.
Historical paraphrase · FAQ 4.0 · 1997 · §10.2.1.2 White linked unusual sensations of movement to sigma activity.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.1.2 · Location and Function in the Brain
This audit retains sigma-3 as a historical label. The modern molecular classification in the cited sources centers on sigma-1 and sigma-2.
Remains a hypothesisAccording to the 2026 audit · edition
What was examined: Schmidt’s structural work and Alon’s identification of TMEM97 provide testable grounds for the modern names.
Limits of the conclusion: The audit’s source coverage is limited. A separate new target requires confirmed molecular identification.
Sources: William White — historical DXM FAQ Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97
Historical paraphrase · FAQ 4.0 · 1997 · §10.2.3 The FAQ mentions sigma-3 as a recently discovered site.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.3 · Sigma 3 Receptors
In the audit, this remains an unconfirmed historical hypothesis. It offers a weak basis for explaining modern DXM findings.
Remains a hypothesisAccording to the 2026 audit · edition
What was examined: For this row, the audit cites the FAQ itself. Its bibliography contains no separate modern primary confirmation.
Limits of the conclusion: This describes the sources in the audit’s bibliography; a comprehensive literature search on the hypothesis lies outside its scope.
Sources: William White — historical DXM FAQ
Historical paraphrase · FAQ 4.0 · 1997 · §10.7 White discussed a proposed endogenous ligand called endopsychosin.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.7 · Endopsychosin and the Big Picture
The main association remains valid. DXM and DXO differ in binding profiles, while each target’s precise contribution to human effects remains a research question.
RetainedAccording to the 2026 audit · edition
What was examined: Carbonaro’s and Shram’s papers describe controlled studies of DXM effects in humans. Xiao provides in-vitro binding data; the Auvelity label includes NMDA in its pharmacology description.
Limits of the conclusion: Plasma concentration, laboratory affinity and receptor occupancy in the brain are different measures. Relating them requires an appropriate model and data.
Sources: Xiao — DXM and DXO target binding Carbonaro — DXM effects in humans Shram — ketamine comparison Auvelity — current label
Historical paraphrase · FAQ 4.0 · 1997 · §9.2.4 The FAQ gives NMDA an important role in dissociative effects.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.4 · Contribution of the NMDA Receptor
The scheme is best retained as a historical model. DXM and DXO concentrations, binding and functional effects describe different aspects of the substances’ actions.
Remains a hypothesisAccording to the 2026 audit · edition
What was examined: Xiao compares DXM and DXO targets in vitro. These measurements differ from receptor-occupancy data in the living brain.
Limits of the conclusion: The original scheme was a qualitative proposal. This audit provides no established thresholds for sequential target activation across plateaus.
Sources: William White — historical DXM FAQ Xiao — DXM and DXO target binding
Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 White proposed a qualitative sequence of target involvement, including PCP2, and qualified it as approximate.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.3.1 · Plateaus 1-3: Multiple Receptors
The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.
The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.
Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.